Shares of Capricor Therapeutics Inc. (CAPR) are soaring over 26% in pre-market today, after the company announced it is providing CAP-1002, its novel cell therapy to patients with advanced COVID-19 under the compassionate use pathway.
from RTT - Before the Bell https://ift.tt/2JCHjzK
via IFTTT
No comments:
Post a Comment